ClinicalTrials.gg
RecruitingNCT06300762Updated Jan 31, 2025

RCT Exudate Management Cutimed Sorbion Product Range

An interventional study of Superabsorbent dressing application in Venous Leg Ulcer, sponsored by BSN Medical GmbH. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by BSN Medical GmbH · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Varicose Ulcer with a site in United Kingdom — 3 open to participants now, 6 under way, 1 of them phase 3. Varicose Ulcer · United Kingdom.

Planned enrollment
10th of 32
152 · median 80
Started
2024
with 2 others
No phase
25 of 38
2 open now
Registered
34th of 38
by date
Lead sponsor
1 of 38
BSN Medical GmbH

Among the 38 studies in Varicose Ulcer with a site in United Kingdom, this one is the 10th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2024, is one of 25 with no phase, and was the 34th registered.

Varicose Ulcer

371 studies on the registry are indexed under Varicose Ulcer; 75 are open to participants now.

Browse Varicose Ulcer studies →

Open to participants now

3 of the 38 studies in Varicose Ulcer with a site in United Kingdom are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 50 Varicose Ulcer studies recruiting now, 40 (80%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Varicose Ulcer with a site in United Kingdom, or all of them as a file.
02

Study summary

The fluid handling capacity of superabsorbent dressings varies depending on the design and construction. The use of effective advanced wound dressings is a promising strategy to achieve adequate absorption of wound exudate and malodour promoting wound healing. The aim of the current study is to determine whether there is a difference in the clinical performance of exudate absorption with two commonly used CE-marked superabsorbent dressings when used on VLUs in routine wound care.

As primary objective the dressing´s absorption performance and its ability to prevent skin maceration and leakage of the wound dressing will be investigated.

03

Conditions studied

  • Venous Leg Ulcer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is informed about the trial, understands the nature of the study and provides written prior to study enrolment
  2. Participant is mentally and physically able to participate in this study
  3. Men, women, diverse ≥ 18 years
  4. Participant complies with study visit schedule
  5. Participant agrees to comply with all standard therapies (e.g., with regards to compression therapy)
  6. Participant suffers from lower leg ulcer* (including the ankle but not the feet) indicated to be treated with the study deviceinvestigational devices, requiring compression and fulfilling the following:
  7. Ulcer is not younger than 4 weeks and not older than 1 year
  8. Ulcer is ranging between 2 cm2 and 800 cm2
  9. One side of the ulcer is not extending 40 cm
  10. Depth of ulcer \< 2 cm
  11. Ankle-brachial pressure index (ABPI) of >0.8 and ≤1.3, measurement not older than 12 months * Participants with more than one ulcer are eligible for inclusion, however only one ulcer per patient will be included in the study.

Exclusion criteria

Exclusion Criteria:

  1. Participant already participates in this study with one ulcer (only one ulcer per participant is allowed)
  2. Participant is expected not to be willing or able to follow the study outlines and requirements
  3. Participant suffers from systemic infectious disease(s) known to negatively influence wound healing, such as AIDS
  4. Participant is undergoing an immuno-compromising therapy, such as systemic antineoplastic drugs and/or systemic
  5. Participant uses any medication that could potentially delay the wound healing ability
  6. Participant is an employee (staff or student) of the hospital site (institute) or the sponsor or is in a dependent relationship with a member of site or sponsor staff, e.g. child, spouse etc.
  7. Participant is pregnant or currently breastfeeding
  8. Participant reporting (and/or suspected by investigator) addiction from alcohol or drugs or is substituted e.g., by Methadone
  1. Participant suffers from alcohol or drug addiction or is substituted e.g., by Methadone 9. Participant is or has been included in another clinical investigation with medical devices or pharmaceutical drugs at present or during the past 30 days 10. Participant with a history of sensitivity to any of the components of the study product 11. Participant whose leg ulcers are clinically infected (e.g., erysipelas) or malignant 12. Study ulcer requiring negative pressure wound therapy or hyperbaric oxygen during the trial 13. The ulcer has exposed bone, tendon, ligaments and/or joint 14. History of radiation at the study ulcer site 15. Participant's lesion is a primary skin cancer 16. Participant's lesion is the manifestation of a
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Cutimed Sorbion products

    Within this arm the Cutimed Sorbion (Cutimed® Sorbion® Sachet/Sana/Border) products will be used for exudate managment.

    Device: Superabsorbent dressing application

  • Active comparator
    Zetuvit (RespoSorb) products

    Within this arm the comperator products Zetuvit® Plus/(RespoSorb® Super), Zetuvit® Plus Silicone/(RespoSorb® Silicone) and Zetuvit® Plus Silicone Border/(RespoSorb® Silicone Border) will be used for exudate management.

    Device: Superabsorbent dressing application

Interventions

  • DeviceSuperabsorbent dressing application

    Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate

06

What researchers measure

Primary outcomes

  1. Exudate management performance

    Capability to main exudate uptake and retention as well as leakage prevention

    Time frame: up to 30 days

Secondary outcomes

  1. Dressing change frequency

    Number of required intermediate dressing changes between study visits and assessement fo reasons for

    Time frame: up to 30 days

  2. Moisture-associated skin damages

    Occurrence of moisture-associated skin damages

    Time frame: up to 30 days

  3. Occurrence clinical relevant peri-wound skin changes

    Effect of product use on peri-wound skin such as reddening, swelling, clinical relevant skin detoriations

    Time frame: up to 30 days

  4. Changes in wound tissue and general wound pain

    Effect of product use on the wound considering wound tissue and slough on the wound as well as the general wound pain assessed using a 11 visual analogue scale from 0-10 (0= not pain, 10=most imaginable pain for the participant)

    Time frame: up to 30 days

  5. Need for debridement after product removal

    Evaluation of the soft debridement effect of Cutimed Sorbion products during dressing removal: is the soft debrimdent supporting wound cleansing and eases addtional wound debridement

    Time frame: up to 30 days

  6. Patient satisfaction with treatment and product

    Patient´s impressions about treatment and felt protection for leakage when using the product and assessment of individually felt wearing comfort

    Time frame: final study visit

  7. HCP satisfaction with treatment and product

    HCP´s satisfaction with treatment and product performance to manage wound exudate, check if treatment need have been met be the product

    Time frame: final study visit

  8. Changes in quality of life using the "Wound-QoL 14" (short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments)

    Fourteen items are scored using a Likert-type scale as either 'not at all', 'a little', 'moderately', 'quite a lot' or 'very much'. Item data are calculated building a global score and the 3 subscores "Body", "Psyche/Well-being" and the "Everyday life". In increase in quality of life is indicated by decreasing sub- and/or global score.

    Time frame: day 0 and day 30

07

Study locations

3 of 3 sites recruiting
  • Niels Stensen Klinik, Christliches-Klinikum-Melle
    Melle, Niedersachsten 49624, Germany
    Recruiting
    • Jan Heggemann · Contact
    • Sabine Guth · Contact
  • Mid Yorkshire Teaching NHS Trust Pinderfields Hospital
    Wakefield, West Yorkshire WF1 4DG, United Kingdom
    Recruiting
    • Martin Sylvester · Contactnn@nn.nn · 800-555-5555
  • Northumbria Healthcare NHS Foundation Trust
    Ashington, NE63 0HP, United Kingdom
    Recruiting
    • Debera Drew · Contactnn@nn.dd · 800-555-5555
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Nov 2025, 15 months after the start.

Of 67 industry-sponsored interventional studies with no phase under Varicose Ulcer, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 15 months is below that.

Counting every sponsor, half of 134 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2024
First posted
Mar 8, 2024
StartActual
Aug 10, 2024
Primary completionEst.
Nov 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06300762
Lead sponsor
BSN Medical GmbH
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Aug 10, 2024
Primary completion
Nov 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jan 31, 2025

Study contacts

Hardy Schweigel, PhD
Contact
hardy.schweigel@essity.com
+491522 ext. 7752954
Sandra Tobisch
Contact
sandra.tobisch@essity.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion